Editorial | Circulating tumor cell burden as a component of staging in multiple myeloma: ready for prime time? 4 Jul, 2022 | 11:48h | UTC Circulating Tumor Cell Burden as a Component of Staging in Multiple Myeloma: Ready for Prime Time? – Journal of Clinical Oncology Original Studies: Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma – Journal of Clinical Oncology High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma – Journal of Clinical Oncology Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile – Journal of Clinical Oncology